摘要
目的观察抗精子蛋白17单克隆抗体(anti-Sperm protein 17 monoclonal antibody,anti-Sp17mAb)对卵巢癌细胞系SKOV-3的体外抗肿瘤活性和机制。方法采用MTT法观察抗anti-Sp17 mAb对肿瘤细胞SKOV-3的细胞毒作用;以外周血单个核细胞PBMCs为效应细胞,SKOV-3为靶细胞,在效靶比分别为80∶1、40∶1和20∶1的条件下,观察anti-Sp17 mAb的抗体依赖性细胞介导的细胞毒作用;以SKOV-3为靶细胞,加入浓度为2.5%、5%、10%和20%的健康人新鲜血清作为补体,观察单抗的补体依赖性细胞毒性。结果 anti-Sp17 mAb对SKOV-3无明显细胞毒作用;与对照组相比,单抗对SKOV-3的ADCC作用呈剂量依赖关系,在效靶比为80∶1,孵育24 h后,细胞生长抑制率约为22%;补体的加入也可显著提高单抗对SKOV-3细胞生长的抑制率,在血清浓度为5%,单抗浓度为10μg/ml时抑制率达到了40%。结论 anti-Sp17 mAb对表达Sp17蛋白的卵巢癌细胞株SKOV-3具有明显的ADCC和CDC效应。
Objective To investigate the inhibitory effect and mechanism of anti-Sp17 monoclonal antibody（mAb） on the growth of human ovarian cancer cells SKOV-3 in vitro.Methods Viability was assessed with the 3-（4,5-dimethylthiazol-2-yl）-2,5-diphenyltetrazolium bromide（MTT） assay after treatment with anti-Sp17 mAb.The ADCC and CDC activities of anti-Sp17 mAb were monitored using SKOV-3 cells as targets,healthy human peripheral blood monocytes and healthy human serum as effectors.ResultsOur preliminary results indicated that direct cytotoxicity of anti-Sp17 mAb against ovarian cancer cells was very low.However,the cytotoxic action of anti-Sp17 mAb mediated by PBMC,as ADCC,or mediated by human serum,as CDC,was noted in investigation of SKOV-3 cells.Conclusion anti-Sp17 mAb could provide a useful tool against ovarian cancer,and may provide insight into the development of low side-effect targeting therapy for this malignant disease.
出处
《肿瘤防治研究》
CAS
CSCD
北大核心
2012年第11期1297-1300,共4页
Cancer Research on Prevention and Treatment
基金
国家自然科学基金资助项目(81101978
30670599)
南京军区医学科学技术"十一五"研究计划重点资助项目(06Z43)
